# A Phase 3 Randomized Study Comparing Talquetamab SC in Combination With Daratumumab SC and Pomalidomide (Tal-DP) or Talquetamab SC in Combination With Daratumumab SC (Tal-D) Versus Daratumumab SC, Pomalidomide and Dexamethasone (DPd), in Participants With Relapsed or Refractory Multiple Myeloma who Have Received at Least 1 Prior Line of Therapy

| | | |
|---|---|---|
| **Estado** | **Tipo de Participantes** | **Rangos de Edad** |
| Fin Reclutamiento | No aportado | Mayores de 64 , Adultos (18-64 años) |
| **Género** | **Fases** | **Participantes esperados** |
| Ambos | Fase III | 553 |
| **Resultados** | **Bajo nivel intervención** | **Enfermedad rara** |
| Sin resultados | No | Si |
| **Cobertura geográfica** | **Ámbitos del ensayo** | **Terapia avanzada** |
| Sin determinar | tratamiento, seguridad, eficacia, farmacocinética, farmacodinamica | NO |

# Información

## Identificador
2023-503467-41-00 (CTIS)

## Cod. Protocolo
64407564MMY3002

Transicionado 2021-000202-22

## Área terapéutica
Enfermedades [C] - Cáncer [C04]|

## Enfermedad investigada
Relapsed or Refractory Multiple Myeloma

## Título Científico

A Phase 3 Randomized Study Comparing Talquetamab SC in Combination With Daratumumab SC and Pomalidomide (Tal-DP) or Talquetamab SC in Combination With Daratumumab SC (Tal-D) Versus Daratumumab SC, Pomalidomide and Dexamethasone (DPd), in Participants With Relapsed or Refractory Multiple Myeloma who Have Received at Least 1 Prior Line of Therapy

## Justificación

No aportado

## Objetivo Principal

To compare the efficacy of Tal-DP and Tal-D, respectively, with DPd

## Variables de Evaluación Primaria

Progression-Free Survival

## Momentos temporales de evaluación primaria

No aportado

## Objetivo Secundario

No aportado

## Variables de Evaluación Secundaria

No aportado

## Momentos temporales de evaluación secundaria

No aportado

## Criterios de Inclusión

Documented multiple myeloma as defined: a) Multiple myeloma diagnosis according to the International Myeloma Working Group (IMWG) diagnostic criteria and b) Measurable disease at screening as defined by any of the following: i) Serum M-protein level greater than or equal to (>=) 0.5 grams per deciliter (g/dL) (central laboratory); ii) Urine M-protein level >= 200 milligram (mg) per 24 hours (central laboratory); iii) Light chain multiple myeloma

without measurable M-protein in the serum or the urine: serum immunoglobulin free light chain >= 10 milligram per deciliter (mg/dL) (central laboratory), and abnormal serum immunoglobulin kappa lambda free light chain ratio Relapsed or refractory disease as defined by: i) Relapsed disease is defined as an initial response to prior treatment, followed by confirmed progressive disease by IMWG criteria greater than (>) 60 days after cessation of treatment; ii) Refractory disease is defined as less than (<) 25 percent (%) reduction in monoclonal paraprotein (M-protein) or confirmed progressive disease by IMWG criteria during previous treatment or less than or equal to (<=) 60 days after cessation of treatment Received at least 1 prior line of antimyeloma therapy including a proteasome inhibitor (PI) and lenalidomide. Participants who have received only 1 prior line of antimyeloma therapy must be considered lenalidomide-refractory (that is, have demonstrated progressive disease by IMWG criteria on or within 60 days of completion of lenalidomide-containing regimen). Participants who have received >=2 prior lines of antimyeloma therapy must be considered lenalidomide exposed Documented evidence of progressive disease based on investigator's determination of response by the IMWG criteria on or after their last regimen Have an Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1, or 2 at screening and immediately prior to the start of administration of study treatment

## Criterios de Exclusión

Contraindications or life-threatening allergies, hypersensitivity, or intolerance to study drug excipients Disease is considered refractory to an anti-cluster of differentiation 38 (CD38) monoclonal antibody as defined per IMWG consensus guidelines (progression during treatment or within 60 days of completing therapy with an anti-CD38 monoclonal antibody) Received prior pomalidomide therapy A maximum cumulative dose of corticosteroids to >=140 milligrams (mg) of prednisone or equivalent within 14-day period before the first dose of study drug Known active central nervous system (CNS) involvement or exhibits clinical signs of meningeal involvement of multiple myeloma. If either is suspected, negative whole brain magnetic resonance imaging (MRI) and lumbar cytology are required Plasma cell leukemia (per IMWG criteria) at the time of screening, Waldenström's macroglobulinemia, polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes (POEMS syndrome), or primary amyloid light chain amyloidosis

# Calendario

(Última actualización: 23/01/2026)

| Autorización | Inicio de Ensayo | Inclusión Primer Paciente | Interrumpido | Reiniciado |
|---|---|---|---|---|
| 26/10/2022 | 03/11/2022 | 08/11/2022 | No aportado | No aportado |

| Fin de reclutamiento | Fin prematuro (España) | Fin prematuro (Global) | Fin del ensayo en España | Fin del ensayo global |
|---|---|---|---|---|
| 19/03/2024 | No aportado | No aportado | No aportado | No aportado |

# Promotor

### Janssen - Cilag International Belgium

**Turnhoutseweg 30**

**Contact Person**

CTIS Point of Contact

**+31717996133**

**CTISadmin@its.jnj.com**

**Monetary support: N/A**

**Tipo de promotor: Comercial**

# Ceim

### CEIm de la Comunidad Foral de Navarra

**C/ Irunlarrea, 3 31008 Pamplona**

**ceic@cfnavarra.es**

# Centros

No iniciado (--/--/----)

**Clinica Universidad De Navarra**

Pamplona

NAVARRA

Servicio de Hematología

Activo (29/08/2023)

**Clínica Universidad De Navarra**

Pamplona/Iruña

NAVARRA

Activo (15/11/2022)

**Complejo Asistencial Universitario De Salamanca**

Salamanca

SALAMANCA

Activo (12/12/2022)

**Complejo Hospitalario Universitario De Canarias**

San Cristóbal de La Laguna

STA. CRUZ DE TENERIFE

No iniciado (--/--/----)

**Fundacio Institut De Recerca De L Hospital De La Santa Creu I Sant Pau**

Barcelona

BARCELONA

Servicio de Hematología

Activo (28/11/2022)

**HOSPITAL CLINIC DE BARCELONA**

Barcelona

BARCELONA

No iniciado (--/--/----)

**Hospital Clinic De Barcelona**

Barcelona

BARCELONA

Servicio de Hematología

Activo (22/12/2022)

**HOSPITAL CLINICO UNIVERSITARIO VIRGEN DE LA ARRIXACA**

Murcia

MURCIA

No iniciado (--/--/----)

**Hospital De Jerez De La Frontera**

Jerez De La Frontera

CÁDIZ

Servicio de Hematología

Activo (03/11/2022)

**HOSPITAL DE LA SANTA CREU I SANT PAU**

Barcelona

BARCELONA

Activo (19/01/2023)

**HOSPITAL DE LEON (COMPLEJO ASISTENCIAL UNIVERSITARIO DE LEON)**

León

LEÓN

No iniciado (--/--/----)

**Hospital Germans Trias I Pujol**

Badalona

BARCELONA

Servicio de Hematología

Activo (09/03/2023)

**HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL DE BADALONA**

Badalona

BARCELONA

No iniciado (--/--/----)

**Hospital Universitari Vall D Hebron**

Barcelona

BARCELONA

Servicio de Hematología

Activo (23/11/2022)

**HOSPITAL UNIVERSITARI VALL D'HEBRON**

Barcelona

BARCELONA

No iniciado (--/--/----)

**Hospital Universitario De Canarias**

La Laguna

STA. CRUZ DE TENERIFE

Servicio de Hematología

Activo (03/11/2022)

**HOSPITAL UNIVERSITARIO DE JEREZ DE LA FRONTERA**

Jerez de la Frontera

CÁDIZ

Cerrado (16/05/2024)

**HOSPITAL UNIVERSITARIO DE LA PRINCESA**

Madrid

MADRID

No iniciado (--/--/----)

**Hospital Universitario De Leon**

Leon

LEÓN

Servicio de Hematología

No iniciado (--/--/----)

**Hospital Universitario De Salamanca**

Salamanca

SALAMANCA

Servicio de Hematología

Activo (25/11/2022)

**HOSPITAL UNIVERSITARIO DR. PESET ALEIXANDRE**

València

VALENCIA

No iniciado (--/--/----)

**Hospital Universitario Dr Peset Aleixandre**

Valencia

VALENCIA

Servicio de Hematología

Cerrado (29/01/2025)

**Hospital Universitario Hm Sanchinarro**

Madrid

MADRID

Cerrado (16/05/2024)

**Hospital Universitario Ramón Y Cajal**

Madrid

MADRID

Activo (16/12/2022)

**HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA**

Málaga

MÁLAGA

No iniciado (--/--/----)

**Hospital Universitario Virgen De La Victoria**

Malaga

MÁLAGA

Servicio de Hematología

Activo (18/11/2022)

**HOSPITAL UNIVERSITARIO 12 DE OCTUBRE**

Madrid

MADRID

No iniciado (--/--/----)

**Hospital Universitario 12 De Octubre**

Madrid

MADRID

Servicio de Hematología

No iniciado (--/--/----)

**University Clinical Hospital Virgen De La Arrixaca**

Murcia

MURCIA

Servicio de Hematología

# Medicamentos

### JNJ-64407564
SOLUTION FOR INJECTION
SUBCUTANEOUS USE

-

Principios Activos: N/A

Huérfano Experimental

### Pomalidomide
CAPSULE, HARD
ORAL USE

-

Principios Activos: N/A

Experimental

### Privigen 100 mg/ml solution for infusion
SOLUTION FOR INFUSION
INTRAVENUS USE

Código ATC: J06BA02 - INMUNOGLOBULINAS HUMANAS NORMALES PARA ADM. INTRAVASCULAR

Principios Activos: N/A

Experimental

### Privigen 100 mg/ml solution for infusion
SOLUTION FOR INFUSION
INTRAVENUS USE

Código ATC: J06BA02 - INMUNOGLOBULINAS HUMANAS NORMALES PARA ADM. INTRAVASCULAR

Principios Activos: N/A

Experimental

### Dexamethason 4 mg JENAPHARM®
TABLET
ORAL USE

Código ATC: H02AB02 - DEXAMETASONA

Principios Activos: N/A

Experimental

### KIOVIG 100 mg/ml solution for infusion
SOLUTION FOR INFUSION
INTRAVENOUS USE

Código ATC: J06BA02 - INMUNOGLOBULINAS HUMANAS NORMALES PARA ADM. INTRAVASCULAR

Principios Activos: N/A

Experimental

### Imnovid 2 mg hard capsules
CAPSULE, HARD
ORAL USE

Código ATC: L04AX06 - POMALIDOMIDA

Principios Activos: N/A

Experimental

### Pomalidomide
CAPSULE, HARD
ORAL USE

-

Principios Activos: N/A

Experimental

### Fortecortin® 2 mg Tabletten
**TABLET**
**ORAL USE**

**Código ATC: H02AB02 - DEXAMETASONA**
**Principios Activos: N/A**

**Experimental**

### Dexamethasone Tablets BP 2.0mg
**TABLET**
**ORAL USE**

**Código ATC: H02AB02 - DEXAMETASONA**
**Principios Activos: N/A**

**Experimental**

### Pomalidomide
**CAPSULE, HARD**
**ORAL USE**

-

**Principios Activos: N/A**

**Experimental**

### KIOVIG 100 mg/ml solution for infusion
**SOLUTION FOR INFUSION**
**INTRAVENOUS USE**

**Código ATC: J06BA02 - INMUNOGLOBULINAS HUMANAS NORMALES PARA ADM. INTRAVASCULAR**
**Principios Activos: N/A**

**Experimental**

### Imnovid 4 mg hard capsules
**CAPSULE, HARD**
**ORAL USE**

**Código ATC: L04AX06 - POMALIDOMIDA**
**Principios Activos: N/A**

**Experimental**

### Imnovid 1 mg hard capsules
**CAPSULE, HARD**
**ORAL USE**

**Código ATC: L04AX06 - POMALIDOMIDA**
**Principios Activos: N/A**

**Experimental**

### Imnovid 3 mg hard capsules
**CAPSULE, HARD**
**ORAL USE**

### KIOVIG 100 mg/ml solution for infusion
**SOLUTION FOR INFUSION**
**INTRAVENOUS USE**

Código ATC: L04AX06 - POMALIDOMIDA
Principios Activos: N/A

Experimental

Código ATC: J06BA02 - INMUNOGLOBULINAS HUMANAS NORMALES PARA ADM. INTRAVASCULAR
Principios Activos: N/A

Experimental

### Privigen 100 mg/ml solution for infusion

SOLUTION FOR INFUSION
INTRAVENOUS USE

Código ATC: J06BA02 - INMUNOGLOBULINAS HUMANAS NORMALES PARA ADM. INTRAVASCULAR
Principios Activos: N/A

Experimental

### JNJ-64407564

SOLUTION FOR INJECTION
SUBCUTANEOUS USE

-
Principios Activos: N/A

Huérfano

Experimental

### DARZALEX 1800 mg solution for injection

SOLUTION FOR INJECTION
SUBCUTANEOUS USE

Código ATC: L01FC01 - DARATUMUMAB
Principios Activos: N/A

Huérfano

Experimental

### Pomalidomide

CAPSULE, HARD
ORAL USE

-
Principios Activos: N/A

Experimental

## Sin resultados

# A Phase 3 Randomized Study Comparing Talquetamab SC in Combination With Daratumumab SC and Pomalidomide (Tal-DP) or Talquetamab SC in Combination With Daratumumab SC (Tal-D) Versus Daratumumab SC, Pomalidomide and Dexamethasone (DPd), in Participants With Relapsed or Refractory Multiple Myeloma who Have Received at Least 1 Prior Line of Therapy

| State | Type of participants | Age Ranges |
|---|---|---|
| End of recruitment | Not provided | Older than 64 , Adults (18-64 years) |
| **Gender** | **Phases** | **Expected Participants** |
| Both | Phase III | 553 |
| **Results** | **Low level of intervention** | **Rare disease** |
| No results | No | Yes |
| **Geographic coverage** | **Areas of the study** | **Advanced therapy** |
| Undetermined | treatment, safety, effectiveness, pharmacokinetics, pharmacodynamics | NO |

## Information

### Identifier
2023-503467-41-00 (CTIS)

### Protocol Code
64407564MMY3002

Transitioned 2021-000202-22

### Therapeutic area
Diseases [C] - Cancer [C04]|

### Investigated Disease
Relapsed or Refractory Multiple Myeloma

### Scientific Title

A Phase 3 Randomized Study Comparing Talquetamab SC in Combination With Daratumumab SC and Pomalidomide (Tal-DP) or Talquetamab SC in Combination With Daratumumab SC (Tal-D) Versus Daratumumab SC, Pomalidomide and Dexamethasone (DPd), in Participants With Relapsed or Refractory Multiple Myeloma who Have Received at Least 1 Prior Line of Therapy

## Rationale

Not provided

## Main Objective

To compare the efficacy of Tal-DP and Tal-D, respectively, with DPd

## Primary Endpoints

Progression-Free Survival

## Temporary moments of secondary assessment

Not provided

## Secondary Objective

Not provided

## Secondary Endpoints

Not provided

## Temporary moments of secondary assessment

Not provided

## Inclusion criteria

Documented multiple myeloma as defined: a) Multiple myeloma diagnosis according to the International Myeloma Working Group (IMWG) diagnostic criteria and b) Measurable disease at screening as defined by any of the following: i) Serum M-protein level greater than or equal to (>=) 0.5 grams per deciliter (g/dL) (central laboratory); ii) Urine M-protein level >= 200 milligram (mg) per 24 hours (central laboratory); iii) Light chain multiple myeloma

without measurable M-protein in the serum or the urine: serum immunoglobulin free light chain >= 10 milligram per deciliter (mg/dL) (central laboratory), and abnormal serum immunoglobulin kappa lambda free light chain ratio Relapsed or refractory disease as defined by: i) Relapsed disease is defined as an initial response to prior treatment, followed by confirmed progressive disease by IMWG criteria greater than (>) 60 days after cessation of treatment; ii) Refractory disease is defined as less than (<) 25 percent (%) reduction in monoclonal paraprotein (M-protein) or confirmed progressive disease by IMWG criteria during previous treatment or less than or equal to (<=) 60 days after cessation of treatment Received at least 1 prior line of antimyeloma therapy including a proteasome inhibitor (PI) and lenalidomide. Participants who have received only 1 prior line of antimyeloma therapy must be considered lenalidomide-refractory (that is, have demonstrated progressive disease by IMWG criteria on or within 60 days of completion of lenalidomide-containing regimen). Participants who have received >=2 prior lines of antimyeloma therapy must be considered lenalidomide exposed Documented evidence of progressive disease based on investigator's determination of response by the IMWG criteria on or after their last regimen Have an Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1, or 2 at screening and immediately prior to the start of administration of study treatment

## Exclusion criteria

Contraindications or life-threatening allergies, hypersensitivity, or intolerance to study drug excipients Disease is considered refractory to an anti-cluster of differentiation 38 (CD38) monoclonal antibody as defined per IMWG consensus guidelines (progression during treatment or within 60 days of completing therapy with an anti-CD38 monoclonal antibody) Received prior pomalidomide therapy A maximum cumulative dose of corticosteroids to >=140 milligrams (mg) of prednisone or equivalent within 14-day period before the first dose of study drug Known active central nervous system (CNS) involvement or exhibits clinical signs of meningeal involvement of multiple myeloma. If either is suspected, negative whole brain magnetic resonance imaging (MRI) and lumbar cytology are required Plasma cell leukemia (per IMWG criteria) at the time of screening, Waldenström's macroglobulinemia, polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes (POEMS syndrome), or primary amyloid light chain amyloidosis

# Calendar

(Last Update: 23/01/2026)

| Authorization | Start of Trial | First patient inclusion | Halted | Restarted |
|---|---|---|---|---|
| 26/10/2022 | 03/11/2022 | 08/11/2022 | Not aported | Not aported |

| End of recruitment | Premature end (Spain) | Premature End (Global) | Trial end (Spain) | Trial end (Global) |
|---|---|---|---|---|
| 19/03/2024 | Not aported | Not aported | Not aported | Not aported |

# Sponsor

### Janssen - Cilag International Belgium

**Turnhoutseweg 30**

**Contact Person**

CTIS Point of Contact

**+31717996133**

**CTISadmin@its.jnj.com**

**Monetary support: N/A**

**Sponsor type: Commercial**

# Ceim

### CEIm de la Comunidad Foral de Navarra

**C/ Irunlarrea, 3 31008 Pamplona**

**ceic@cfnavarra.es**

# Sites

not initialized (--/--/----)

**Clinica Universidad De Navarra**

Pamplona

NAVARRA

Servicio de Hematología

Active (29/08/2023)

**Clínica Universidad De Navarra**

Pamplona/Iruña

NAVARRA

Active (15/11/2022)

**Complejo Asistencial Universitario De Salamanca**

Salamanca

SALAMANCA

Active (12/12/2022)

**Complejo Hospitalario Universitario De Canarias**

San Cristóbal de La Laguna

STA. CRUZ DE TENERIFE

not initialized (--/--/----)

**Fundacio Institut De Recerca De L Hospital De La Santa Creu I Sant Pau**

Barcelona

BARCELONA

Servicio de Hematología

Active (28/11/2022)

**HOSPITAL CLINIC DE BARCELONA**

Barcelona

BARCELONA

not initialized (--/--/----)

**Hospital Clinic De Barcelona**

Barcelona

BARCELONA

Servicio de Hematología

Active (22/12/2022)

**HOSPITAL CLINICO UNIVERSITARIO VIRGEN DE LA ARRIXACA**

Murcia

MURCIA

not initialized (--/--/----)

**Hospital De Jerez De La Frontera**

Jerez De La Frontera

CÁDIZ

Servicio de Hematología

Active (03/11/2022)

**HOSPITAL DE LA SANTA CREU I SANT PAU**

Barcelona

BARCELONA

Active (19/01/2023)

**HOSPITAL DE LEON (COMPLEJO ASISTENCIAL UNIVERSITARIO DE LEON)**

León

LEÓN

not initialized (--/--/----)

**Hospital Germans Trias I Pujol**

Badalona

BARCELONA

Servicio de Hematología

Active (09/03/2023)

**HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL DE BADALONA**

Badalona

BARCELONA

not initialized (--/--/----)

**Hospital Universitari Vall D Hebron**

Barcelona

BARCELONA

Servicio de Hematología

Active (23/11/2022)

**HOSPITAL UNIVERSITARI VALL D'HEBRON**

Barcelona

BARCELONA

not initialized (--/--/----)

**Hospital Universitario De Canarias**

La Laguna

STA. CRUZ DE TENERIFE

Servicio de Hematología

Active (03/11/2022)

**HOSPITAL UNIVERSITARIO DE JEREZ DE LA FRONTERA**

Jerez de la Frontera

CÁDIZ

Closed (16/05/2024)

**HOSPITAL UNIVERSITARIO DE LA PRINCESA**

Madrid

MADRID

not initialized (--/--/----)

**Hospital Universitario De Leon**

Leon

LEÓN

Servicio de Hematología

not initialized (--/--/----)

**Hospital Universitario De Salamanca**

Salamanca

SALAMANCA

Servicio de Hematología

Active (25/11/2022)

**HOSPITAL UNIVERSITARIO DR. PESET ALEIXANDRE**

València

VALENCIA

not initialized (--/--/----)

**Hospital Universitario Dr Peset Aleixandre**

Valencia

VALENCIA

Servicio de Hematología

Closed (29/01/2025)

**Hospital Universitario Hm Sanchinarro**

Madrid

MADRID

Closed (16/05/2024)

**Hospital Universitario Ramón Y Cajal**

Madrid

MADRID

Active (16/12/2022)

**HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA**

Málaga

MÁLAGA

not initialized (--/--/----)

**Hospital Universitario Virgen De La Victoria**

Malaga

MÁLAGA

Servicio de Hematología

Active (18/11/2022)

**HOSPITAL UNIVERSITARIO 12 DE OCTUBRE**

Madrid

MADRID

not initialized (--/--/----)

**Hospital Universitario 12 De Octubre**

Madrid

MADRID

Servicio de Hematología

not initialized (--/--/----)

**University Clinical Hospital Virgen De La Arrixaca**

Murcia

MURCIA

Servicio de Hematología

# Medication

### JNJ-64407564
SOLUTION FOR INJECTION
SUBCUTANEOUS USE

-

Active Principles: N/A

Orphan Experimental

### Pomalidomide
CAPSULE, HARD
ORAL USE

-

Active Principles: N/A

Experimental

### Privigen 100 mg/ml solution for infusion
SOLUTION FOR INFUSION
INTRAVENUS USE

ATC code: J06BA02 - INMUNOGLOBULINAS HUMANAS NORMALES PARA ADM. INTRAVASCULAR

Active Principles: N/A

Experimental

### Privigen 100 mg/ml solution for infusion
SOLUTION FOR INFUSION
INTRAVENUS USE

ATC code: J06BA02 - INMUNOGLOBULINAS HUMANAS NORMALES PARA ADM. INTRAVASCULAR

Active Principles: N/A

Experimental

### Dexamethason 4 mg JENAPHARM®
TABLET
ORAL USE

ATC code: H02AB02 - DEXAMETASONA

Active Principles: N/A

Experimental

### KIOVIG 100 mg/ml solution for infusion
SOLUTION FOR INFUSION
INTRAVENOUS USE

ATC code: J06BA02 - INMUNOGLOBULINAS HUMANAS NORMALES PARA ADM. INTRAVASCULAR

Active Principles: N/A

Experimental

### Imnovid 2 mg hard capsules
CAPSULE, HARD
ORAL USE

ATC code: L04AX06 - POMALIDOMIDA

Active Principles: N/A

Experimental

### Pomalidomide
CAPSULE, HARD
ORAL USE

-

Active Principles: N/A

Experimental

### Fortecortin® 2 mg Tabletten
**TABLET**
**ORAL USE**

**ATC code: H02AB02 - DEXAMETASONA**
**Active Principles: N/A**

**Experimental**

### Dexamethasone Tablets BP 2.0mg
**TABLET**
**ORAL USE**

**ATC code: H02AB02 - DEXAMETASONA**
**Active Principles: N/A**

**Experimental**

### Pomalidomide
**CAPSULE, HARD**
**ORAL USE**

-

**Active Principles: N/A**

**Experimental**

### KIOVIG 100 mg/ml solution for infusion
**SOLUTION FOR INFUSION**
**INTRAVENOUS USE**

**ATC code: J06BA02 - INMUNOGLOBULINAS HUMANAS NORMALES PARA ADM. INTRAVASCULAR**
**Active Principles: N/A**

**Experimental**

### Imnovid 4 mg hard capsules
**CAPSULE, HARD**
**ORAL USE**

**ATC code: L04AX06 - POMALIDOMIDA**
**Active Principles: N/A**

**Experimental**

### Imnovid 1 mg hard capsules
**CAPSULE, HARD**
**ORAL USE**

**ATC code: L04AX06 - POMALIDOMIDA**
**Active Principles: N/A**

**Experimental**

### Imnovid 3 mg hard capsules
**CAPSULE, HARD**
**ORAL USE**

### KIOVIG 100 mg/ml solution for infusion
**SOLUTION FOR INFUSION**
**INTRAVENOUS USE**

ATC code: L04AX06 - POMALIDOMIDA

Active Principles: N/A

Experimental

ATC code: J06BA02 - INMUNOGLOBULINAS HUMANAS NORMALES PARA ADM. INTRAVASCULAR

Active Principles: N/A

Experimental

## Privigen 100 mg/ml solution for infusion

SOLUTION FOR INFUSION

INTRAVENOUS USE

ATC code: J06BA02 - INMUNOGLOBULINAS HUMANAS NORMALES PARA ADM. INTRAVASCULAR

Active Principles: N/A

Experimental

## JNJ-64407564

SOLUTION FOR INJECTION

SUBCUTANEOUS USE

-

Active Principles: N/A

Orphan

Experimental

## DARZALEX 1800 mg solution for injection

SOLUTION FOR INJECTION

SUBCUTANEOUS USE

ATC code: L01FC01 - DARATUMUMAB

Active Principles: N/A

Orphan

Experimental

## Pomalidomide

CAPSULE, HARD

ORAL USE

-

Active Principles: N/A

Experimental

# No results